Savara Stock

Savara EBIT

The EBIT of Savara (SVRA) as of Jul 29, 2026 is -123.55 M USD. In the previous year, EBIT was -103.20 M USD — a change of 19.72% (lower).

EBIT

-123.55 MUSD

YoY

19.72%

Last updated:

In 2026, Savara's EBIT was -123.55 M USD, a 19.72% increase from the -103.20 M USD EBIT recorded in the previous year.

The Savara EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2023
-60.01 base
Jan 1, 2024
-103.20 base
Jan 1, 2025
-123.55 base
Jan 1, 2026 (e)
-111.68 base
Jan 1, 2027 (e)
-40.03 base
Jan 1, 2028 (e)
24.04 base
Jan 1, 2029 (e)
149.56 base
Jan 1, 2030 (e)
259.43 base
YEAREBIT (M USD)
2030 est 259.43
2029 est 149.56
2028 est 24.04
2027 est -40.03
2026 est -111.68
2025 -123.55
2024 -103.20
2023 -60.01
2022 -38.84
2021 -40.73
2020 -48.13
2019 -79.03
2018 -70.05
2017 -32.27
2016 -10.83
2015 -39.37
2014 -29.28
2013 -21.54
2012 -15.63
2011 -13.40
2010 -8.54
2009 -11.29
2008 -27.31
2007 -24.31
2006 -29.84
Access this data via the Eulerpool API

Savara Revenue

Savara Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-60.01 M USD
-54.70 M USD
Jan 1, 2024
0.00 USD
-103.20 M USD
-95.88 M USD
Jan 1, 2025
0.00 USD
-123.55 M USD
-118.84 M USD
Jan 1, 2026 (e)
3.18 M USD
-111.68 M USD
-105.93 M USD
Jan 1, 2027 (e)
83.42 M USD
-40.03 M USD
-58.55 M USD
Jan 1, 2028 (e)
207.46 M USD
24.04 M USD
26.40 M USD
Jan 1, 2029 (e)
375.26 M USD
149.56 M USD
106.92 M USD
Jan 1, 2030 (e)
538.11 M USD
259.43 M USD
184.14 M USD

Savara Margins

Savara stock margins

The Savara margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Savara. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Savara.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
-2.90 M %
- %
- %
Jan 1, 2024
-2.90 M %
- %
- %
Jan 1, 2025
-2.90 M %
- %
- %
Jan 1, 2026 (e)
-2.90 M %
-3,513.19 %
-3,332.31 %
Jan 1, 2027 (e)
-2.90 M %
-47.99 %
-70.19 %
Jan 1, 2028 (e)
-2.90 M %
11.59 %
12.72 %
Jan 1, 2029 (e)
-2.90 M %
39.86 %
28.49 %
Jan 1, 2030 (e)
-2.90 M %
48.21 %
34.22 %

Savara Stock analysis

What does Savara do? Savara Inc is a US biotechnology company specializing in the development and commercialization of therapies for rare respiratory diseases. The company was founded in 2007 and is headquartered in Austin, Texas. Savara initially focused on treating cystic fibrosis, a genetic disease that can cause severe lung problems. The company developed an innovative therapy based on the use of liposomes, tiny bubbles that can deliver medication directly to the lungs. This method was considered promising and received orphan drug status from the FDA, meaning it is intended for the treatment of rare diseases. However, due to high costs associated with developing and approving a new medication for cystic fibrosis, Savara decided to redefine its goals and focus on other rare respiratory diseases. The company's business model is based on identifying promising therapy approaches for these diseases and developing them into approvable medications. Savara collaborates closely with leading experts and scientists in the field of respiratory diseases. Its main therapy areas include cystic fibrosis, pulmonary fibrosis, and rare lung diseases. Savara has a special focus on developing liposome-based therapies, which have the potential to target the affected areas in the lungs and enhance the effects of other medications. Currently, the company offers three products: - AeroVanc: A liposome-based inhaled antibiotic used to treat cystic fibrosis-induced chronic lung infections. AeroVanc is the first FDA-approved medication in Savara's history. - Molgradex: A recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) being developed for the treatment of autoimmune pulmonary alveolitis (also known as extrinsic allergic alveolitis). - AVAIL: A liposome-based inhaled antibiotic currently in Phase II of clinical development, being developed to treat non-tuberculous mycobacterial (NTM) lung infections. Savara has also formed partnerships with other companies and organizations to advance its research and development. Partners include the Cystic Fibrosis Foundation, the National Institutes of Health (NIH), and the European Respiratory Society. In summary, Savara Inc is a biotechnology company focused on developing therapies for rare respiratory diseases. The company has developed a promising technology platform and collaborates closely with leading experts and scientists in the field. Savara has a range of products on the market, including the first FDA-approved medication in the company's history. Savara is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Savara's EBIT

Savara's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Savara's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Savara's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Savara’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Savara stock

EBIT of Savara is -123.55 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Savara

All Key Metrics — Savara